GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease.
about
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesPotentiation of NMDA receptor-mediated transmission in striatal cholinergic interneuronsCholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditionsNMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.The GABAA receptor agonist muscimol induces an age- and region-dependent form of long-term depression in the mouse striatum.Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: implication for Parkinson's disease.CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons.NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate.Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine.
P2860
Q26852311-039BC255-C330-4CDD-8057-B252044FA9A6Q28649940-C11EE866-A57F-42D0-9DE6-C8820606BC1CQ36042479-A97F61B4-6F37-4F3D-ADE8-75FBF660BDF1Q41420806-A5AAF527-8751-4DB3-9C28-39E40DC9F1FBQ41748040-4B3116F1-C22F-47DF-B335-BE0651B11FEBQ42023708-64341786-5508-421A-B28D-72D54664233DQ47920457-1DD90A7A-AB15-41BA-9437-44FB5F58A443Q48013669-F6FBE49F-8C49-4501-A67D-3B6CE601A63EQ52632229-EB7CB97F-ADB3-43E1-88E5-87649ED95385Q52653144-BA446EB0-5218-4A4C-B794-E5F255A5D049
P2860
GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
GluN2D-containing NMDA recepto ...... ation for Parkinson's disease.
@en
GluN2D-containing NMDA recepto ...... ation for Parkinson's disease.
@nl
type
label
GluN2D-containing NMDA recepto ...... ation for Parkinson's disease.
@en
GluN2D-containing NMDA recepto ...... ation for Parkinson's disease.
@nl
prefLabel
GluN2D-containing NMDA recepto ...... ation for Parkinson's disease.
@en
GluN2D-containing NMDA recepto ...... ation for Parkinson's disease.
@nl
P2860
P356
P1476
GluN2D-containing NMDA recepto ...... ation for Parkinson's disease.
@en
P2093
Xiaoqun Zhang
Ze-Jun Feng
P2860
P304
P356
10.1111/JNC.12658
P407
P577
2014-02-11T00:00:00Z